Second-Line Treatment of ITP in Children Under 18 with Mucosal Bleeding or Reduced Quality of Life

This protocol addresses the management of immune thrombocytopenia (ITP) specifically in children younger than 18 years who present with non-life-threatening mucosal bleeding and/or a diminished health-related quality of life, and who have not responded to first-line treatment.

Clinical scenario: Paediatric patient (age <18 years) with ITP lasting ≥3 months, experiencing non-life-threatening mucosal bleeding and/or meaningfully reduced quality of life, with inadequate response to prior first-line therapy.

Treatment approach (partial)
Second-line escalation in this population begins with a thrombopoietin receptor agonist as the first option — the full sequencing, agent selection, and management details are available in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

In children with newly diagnosed ITP who have non-life-threatening mucosal bleeding and/or diminished health-related quality of life, the ASH guideline panel suggests corticosteroids rather than intravenous immunoglobulin or anti-D immunoglobulin.

In children with ITP lasting ≥3 months who have non-life-threatening mucosal bleeding and/or diminished health-related quality of life and do not respond to first-line treatment, the ASH guideline panel suggests the following options for second-line therapies presented in the order they should be pursued: Thrombopoietin receptor agonist (eltrombopag or romiplostim).

View source ↗